Assessing heart health in COVID-19 survivors over 50
Official title: Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
Run by Baker Heart and Diabetes Institute · NCT04983823 · Data updated 2026-11-12
This study is testing a new heart health program for COVID-19 survivors over 50 to see if it can help them improve their heart function and reduce their risk of heart failure.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 85 Years |
| Sex | All |
| Enrollment | 820 (estimated) |
| Sponsor | Baker Heart and Diabetes Institute Academic / other |
| Locations | 1 site (Melbourne, Victoria) |
| Status | Recruiting |
| Started | November 18, 2021 |
| Main results expected | July 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | October 3, 2025 |
| Trial ID | NCT04983823 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals over 50 years old who have a history of COVID-19 infection.
✕Probably not a fit
Patients with significant heart valve issues, previous heart failure, or other serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective study aims to identify and improve functional capacity in survivors of COVID-19 who are over 50 years old. Participants will be randomized to a cardio-COVID disease management plan (CC-DMP) that includes VO2 testing and imaging to detect reduced functional capacity and subclinical left ventricular dysfunction. The program will also involve clinical reviews for optimal risk factor control and exercise interventions over a 24-month period. The study seeks to demonstrate the feasibility of this approach in reducing heart failure risk among COVID-19 survivors.
Why it matters
Potential benefit: If successful, this study could lead to improved heart health and reduced risk of heart failure in COVID-19 survivors.
How similar studies have gone: Other studies have shown promising results in managing cardiovascular health in COVID-19 survivors, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. History of COVID-19 infection 2. Live within a geographically accessible area for follow-up Exclusion Criteria: 1. Valvular stenosis or regurgitation of \>moderate severity 2. History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2) 3. Inability to acquire interpretable images (identified from baseline echo) 4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors 5. Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial 6. Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both. 7. Mobility impairment that would impact participants' ability to perform exercise 8. Unable to provide written informed consent to participate in this study
Where it's running
-
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia Recruiting
Study contacts
- Principal investigator: Thomas H Marwick, MD,PhD,MPH — Baker Heart and Diabetes Institute
- Study coordinator: Joel Smith, MSc
- Email: joel.smith@baker.edu.au
- Phone: +61385321964
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.